Apply to Innovative Medicines Initiative (IMI) Call 2020, themes 4 and 5 related specifically to cancer.
The Innovative Medicines Initiative is a jointly funded partnership between the European Union, represented by the European Commission, and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The Innovative Medicines Initiative2 Joint Undertaking (IMI2 JU) has been created following the principles below:
Research related to the future of medicine should be undertaken in areas where societal, public health and biomedical industry competitiveness goals are aligned and require the pooling of resources and greater collaboration between the public and private sectors, with the involvement of Small and Medium-sized Enterprises (SMEs).
- Topic 1: Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis
- Topic 2: Innovations to accelerate vaccine development and manufacture
- Topic 3: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)
This topic is part of the IMI AMR Accelerator Programme. Applicants should also read the Questions and Answers on the programme (document last updated November 2019).
- Topic 4: Tumour plasticity
- Topic 5: Proton versus photon therapy for oesophageal cancer – a trimodality strategy
- Topic 6: Handling of protein drug products and stability concerns
For full details of the topics, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Participant Portal) or read the IMI2 – Call 20 Text.
- From EFPIA companies and IMI2 Associated Partners: 140 209 500 €
- From the IMI2 JU: 133 009 000 €
Key dates and deadlines
- Stage 1 submission deadline: 21 April 2020
- Stage 2 submission deadline: 5 November 2020
How to apply
All documents relating to the Call can be found via the Funding and Tenders Portal and the IMI2 Call documents page, in particular the IMI Manual for evaluation, submission and grant award – version 1.7.
Short proposals must be submitted via the electronic submission system of the Funding and Tenders Portal. To start submitting your proposal, simply click on the relevant topic above – this will take you directly to that topic’s page on the Participant Portal. Once there, scroll down and click on ‘Start submission’.
Detailed guidance on how to submit a proposal, including a detailed user manual and frequently asked questions, can be found under the Submit a Proposal section of the Participant Portal Horizon 2020 Online Manual.
Participation of UK-based organisations: As noted on the EU Funding and Tenders Portal, the Withdrawal Agreement as agreed between the European Union and the United Kingdom entered into force on 1 February 2020. In overall terms, on the basis of the Withdrawal Agreement, the UK-based legal entities will continue to be fully eligible to participate and receive funding in the current 2014-2020 EU programmes, including Horizon 2020, as if the UK were a member state until the closure of these programmes, unless security considerations apply. This means that UK beneficiaries can continue – without interruption – to receive grants awarded under the current and previous MFFs until their end dates, even if these are after 2020.
- Sign up for / catch up on the IMI2 – Call 20 webinars.
- Read our tips for applicants and advice on finding project partners.